Key Takeaways

Well-diversified drug pipeline with 52 drugs in late-stage approval - a good hedge for its patent expirations
Kenvue spin off allows JNJ to focus on its more profitable Medical Devices and Pharmaceuticals segments
Continued dividend increases and buybacks are affordable and will help capital returns
Post Kenvue, I expect JNJ to grow revenues by 7.5% p.a. from its new baseline of $84B, and at higher margins
Some risks around litigation, patent expiry and drug success are present

Catalysts

Robust Drug Pipeline: 52 Drugs Racing To The Finish Line In Late-Stage Approval

The key threat to a pharmaceutical stock is the patent expiration of their high value assets. Should a company lack a product pipeline to bolster its future product portfolio, then losing exclusivity to any one drug can be a hit to the business. In the table below, we can see the top selling drugs for JNJ up to 2022.

Statista: JNJ’s sales by top selling drugs

Stelara is expected to get its first competition from biosimilars in the second half of 2023 as the drug’s patent expires. This is a high-value drug for the company bringing in $9.7B in sales, a significant 10.2% of its 2022 revenues. From the list above, I note that Darzalex expires in 2029, Imbruvica in 2028, and Tremfya expires in 2031.

The company has a well-diversified drug pipeline with 45 products in stage 3 approval and 12 products in the (final) registration phase. There is a risk that not all products in the pipeline will get approved, but the number of treatments in the pipeline is a driver of potential future revenues.

Spun Off The Consumer Health Segment To Focus on Growth And Profitability

Johnson & Johnson (JNJ) is a leading healthcare company with a diversified business model and a long track-record of success. The company operates in three segments: Consumer 15.8% of revenue (now spinned off as Kenvue), Medtech 29.5% revenue, Pharmaceutical 54.7% revenue.

SimplyWallSt: JNJ’s sales by revenue segment

In 2023, JNJ spun off its Consumer Health segment into Kenvue, allowing the company to focus on its more profitable Medical Devices and Pharmaceuticals segments. The company will lose the $15.4B consumer health segment by next year's reporting and revenues will drop by around $13B - slightly offset by the growth of the other two segments.

This focus is expected to drive long-term growth, and management has increased revenue growth expectations to 7.5%, starting from a baseline of $84B post separation. The spin-off will reduce JNJ’s share count to 2.557, as it’s expecting a tax-free gain of approximately $20B in Q3 '23 and has received $13.2B as part of the transaction, this would reflect a 7% reduction in shares resulting from a $33B repurchase this year.

While I agree that the remaining business segments have higher margins and growth potential, they also come at a higher risk as the company is now more reliant on drug approvals and patient adoption.

Johnson & Johnson Is Returning More Than Its $4.76 Dividend

JNJ is considered a reliable dividend paying stock with over 50 years of dividend payments. Currently standing at a 2.9% yield, with a $4.76 annual dividend. Before the Kenvue spin-off, the company paid out around $8B in buybacks and $12.8B in dividends, amounting to a total capital return of $21B, representing an adjusted yield of around 5%.

SimplyWallSt: JNJ’s dividend history

I expect the company to be able to successfully maintain and increase its dividends and buybacks in the future, given that it has consistently produced more than $17B in earnings and can afford the capital returns.

Assumptions

I expect the company to grow revenues by 7.5% annually in the next five years, starting from their new $84B baseline post separation, to $120.6B in 2028.
The new business mix has higher margin characteristics, which is why I think JNJ will be able to maintain a 20% profit margin in the future, yielding $24B in earnings in 2028.
I expect around $8B buybacks annually, reducing the share count from 2.557B at the end of 2023 by 2% every year to 2.32B in 2028.
JNJ’s forward PE ratio is 20.8x and the U.S. 10-year biotech median PE is 18.3x. While I believe that JNJ will converge to these averages in the long-term, I think that the business justifies a 22x PE in the next five years because of its growth potential from its diversified drug pipeline.

Risks

Pending lawsuits: JNJ is facing a number of pending lawsuits, including litigation related to its talcum powder products and its role in the opioid crisis. JNJ had proposed to pay $8.9B for a settlement but the case is not resolved yet. These lawsuits could have a material impact on the company.
Patent expirations: Some of JNJ's key patents are expiring in the next few years, which could lead to increased competition and lower sales for those products.
Success of its drug pipeline: JNJ's pharmaceutical business is a major driver of revenue and profits. However, there is no guarantee that JNJ's drug pipeline will be successful.

Rich Drug Pipeline Will Push Revenues and Earnings Higher

Shared on29 Oct 24Fair value Decreased 1.81%

Shared on29 Oct 24
Fair value Decreased 1.81%